Dublin-listed pharma company Elan has announced the first patient dosing in a Phase 2a study of a drug that could be used by people with Down syndrome.
Drug development efforts in this area have been limited so far and there are currently no drugs approved for the treatment of cognitive dysfunction in Down syndrome. Elan’s ELND005 compound is being studied to see if it has potential as a cognitive enhancer that may improve everyday functioning...
Subscribe from just €1 for the first month!
All Digital Access + eReader
Unlimited Access for 1 Month
Then €19.99 a month after the offer period.
€149 For the 1st Year
Unlimited Access for 1 Year
90 Day Pass
Get a Business Account for you and your team